Two Form Vanguard For First US Rivals to Banzel Suspension
Two companies now hold final US approvals for generics of Eisai’s Banzel oral suspension. But patent-litigation settlements could delay the entry of Bionpharma and Hikma to market.
Two companies now hold final US approvals for generics of Eisai’s Banzel oral suspension. But patent-litigation settlements could delay the entry of Bionpharma and Hikma to market.